Both preclinical and clinical studies subsequently showed that intra-tumoral injection of Ad5CMV-p53 leads to the expression of wild-type TP53 in various tumor tissues, resulting in the selective death of cancer cells.31 This evidence concerns the gene TP53 and neoplasm.